FDA Plans to Strengthen Monitoring of Accutane. Part 1

Nov. 24, 2007 — The U.S.
Food and Drug Government (FDA) is increase required monitoring of the
acne drug isotretinoin (Accutane) in an achievement to reduce the risks
of fetal influence and biological process defects associated with use
of the drug by pregnant women.

The
move is in result to the recommendations of an FDA advisory electrical
device earlier this year that urged tighter controls on the drug.

In
February, advisory plug-in members said good monitoring is needed to
excerption women of child-bearing age to prevent them from becoming
pregnant while taking the drug.

The drug was also in the news
recently after a unit of lawmakers called for a ban of the drug last
time unit, and an FDA scientist named it as one of five potentially
dangerous drugs on the social class in congressional asseveration last
week.

Isotretinoin is used to happening severe acne that has not responded to other treatments.
Prescribing accusal and the drug’s recording label warn against use of the drug in pregnant women.

This is a part of article FDA Plans to Strengthen Monitoring of Accutane. Part 1 Taken from "Acne Isotretinoin Accutane" Information Blog